We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Coloradeo Cancer Center. For more information on Dr. Kessler, please visit her bio here. In part one of

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses evolving standards for molecular testing in advanced NSCLC. We would like to

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Translating Molecular Oncology Results into Targeted Therapy Treatment For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom furthers his discussion with Dr. Elizabeth Kessler, from the University of Colorado Cancer Center. For more information on Dr. Kessler, please visit her bio here. In

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Petros Grivas, from the University of Washington and the Fred Hutchinson Cancer Center. For more information on Dr. Grivas, please visit his bio

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.